ImpediMed Limited (ASX: IPD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

ImpediMed Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • ImpediMed Limited (ASX: IPD)
    Latest News

    ⏸️ Investing

    2 growing biotech stocks for your portfolio in 2015

    Neuren Pharmaceuticals Ltd (ASX:NEU) and Impedimed Limited (ASX:IPD) could be just the ticket for improving your portfolio returns in the…

    Read more »

    ⏸️ Investing

    5 ASX stocks smashed by the market today

    ASX closes up 0.1%, but these five were smashed

    Read more »

    ⏸️ Investing

    Here's why this healthcare stock rocketed up 30% yesterday: Is there more to come?

    Impedimed Limited's (ASX:IPD) CEO Richard Carreon said: “This is a real game-changer".

    Read more »

    a woman
    ⏸️ Investing

    4 stocks soaring on the ASX today

    Want to know why some of these stocks are up more than 15%? Here's our view

    Read more »

    Frequently Asked Questions

    No, Impedimed does not pay shareholder dividends at this time.

    Impedimed Limited listed on the ASX on 24 October 2007.

    IPD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About ImpediMed Limited

    Impedimed Ltd (ASX: IPD) is a global leader in the design and manufacture of medical devices that use bioimpedance spectroscopy (BIS) technologies in the non-invasive clinical assessment of fluid and tissue composition.

    The company's products are typically used to assess and monitor lymphedema and heart failure, as well as to measure patients' tissue composition and fluid status. They also have general health applications in weight management, nutritional issues, and assessing bone content.

    As well, Impedimed offers a cloud-based digital platform to manage patient data. The company is based in Australia and generates most of its revenue in North America. 

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    05 Sep 2024 Andrew Grant Buy 600,000 $28,530
    On-market trade.
    30 Aug 2024 Andrew Grant Buy 1,000,000 $49,600
    On-market trade.
    30 Aug 2024 Christine Emmanuel-Donnelly Buy 200,000 $10,000
    On-market trade.
    14 May 2024 Christine Emmanuel-Donnelly Buy 100,000 $8,000
    On-market trade.
    06 May 2024 Andrew Grant Buy 100,000 $8,050
    On-market trade.
    29 Feb 2024 Andrew Grant Buy 100,000 $87,000
    On-market trade.
    28 Feb 2024 Andrew Grant Buy 130,000 $10,920
    On-market trade.
    28 Feb 2024 Christine Emmanuel-Donnelly Buy 121,952 $10,169
    On-market trade.
    13 Dec 2023 Christine Emmanuel-Donnelly Buy 67,857 $9,499
    On-market trade.
    04 Dec 2023 Andrew Grant Buy 70,000 $9,625
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Christine Emmanuel-Donnelly Non-Executive Director Sep 2023
    Ms Emmanuel-Donnelly brings 30 years in IP expertise through commercialisation and strategic in-house intellectual property roles. She has more than 4 years in Board and healthcare governance experience. She is a member of the Risk Committee.
    Steven Chen Chief Medical Officer
    -
    Ashley Munoz Director Human Resources
    -
    Andrew Grant Executive Director VP Product Development & Customer Solutions
    -
    Julie Kuhlken Senior Director Downstream Marketing
    -
    Dennis Schlaht SVP R&D and Technology
    -
    Tim Benkovic SVP Sales & Customer Success
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 177,180,440 8.76%
    HSBC Custody Nominees (Australia) Limited 164,419,200 8.13%
    Jp Morgan Nominees Australia Pty Limited 148,941,253 7.36%
    National Nominees Limited 115,304,879 5.70%
    HSBC Custody Nominees (Australia) Limited i 55,570,348 2.75%
    BNP Paribas Noms Pty Ltd 34,426,377 1.70%
    Sunlora Pty Ltd 32,125,000 1.59%
    Moore Family Nominee Pty Ltd 30,000,000 1.48%
    Mr Hamish Alexander Jones 23,538,705 1.16%
    Mba Investments Pty Ltd 22,490,990 1.11%
    Mr Gregory Wayne Brown 20,300,000 1.00%
    Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken 19,000,000 0.94%
    Bnp Paribas Nominees Pty Ltd i 18,925,694 0.94%
    Pakasoluto Pty Limited 16,011,422 0.79%
    Mr Hsien Michael Soo 15,662,797 0.77%
    First Samuel Ltd Acn 086243567 15,281,508 0.76%
    HSBC Custody Nominees (Australia) Limited A/C 2 14,251,964 0.70%
    Bsd Pty Ltd 13,495,000 0.67%
    Hme Soo Holdings Pty Ltd 12,320,921 0.61%
    Bnp Paribas Nominees Pty Ltd ii 11,693,112 0.58%

    Profile

    since

    Note